Oncimmune Holdings PLC Senior Leadership Team Appointments & Board Change (7292J)

TIDMONC

RNS Number : 7292J

Oncimmune Holdings PLC

06 December 2018

6 December 2018

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Senior Leadership Team Appointments and Board Change

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces the appointment to the Senior Leadership Team of Matthew Hall as Group Chief Financial Officer and Andrew Stewart as General Counsel and Company Secretary.

Andrew Millet has stepped down from the Board as Chief Financial Officer, Director and Company Secretary. Andrew will be available to the Company for the next six months to ensure an orderly transition of his CFO responsibilities.

Matthew Hall is a seasoned finance professional with over 25 years' of corporate finance experience in a number of leading organisations and fast-growing companies. Most recently he was Chief Financial Officer at Tusk Therapeutics and Simbec-Orion Group. Previously, Matthew was Chief Financial Officer at Sphere Medical Holding plc where he was appointed to lead the company's successful IPO and prior to that was Chief Financial Officer of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc. Matthew is a Chartered Accountant with a degree in Economics.

Andrew Stewart is an international business lawyer with extensive healthcare industry experience. Andrew's previous role was at Smith & Nephew plc, where he was responsible for leading the legal teams supporting the group's global M&A efforts and European commercial operations. Before that, he was Chief Counsel, Global Transactions and Corporate at Shire plc. Before joining industry, Andrew spent a number of years in private legal practice, primarily at Clifford Chance. Andrew has extensive experience advising FTSE100 companies and multinationals and has held executive leadership positions. He holds degrees in Law and Science (Biochemistry and Immunology).

Dr Adam Hill, CEO of Oncimmune commented: "The additions to the Senior Leadership Team we are announcing today will help me drive the delivery of Oncimmune's strategy to capitalise on the wide range of opportunities presented by our proprietary autoantibody-based platform. Matthew and Andrew both have highly relevant experience and will support the Board in its day-to-day activities as we set about delivering the next chapter of our Company's strategy over the next three years.

"I would like to thank Andrew Millet for his 15 years of service to Oncimmune. Andrew has been instrumental in supporting Oncimmune's journey to date, helping the Company through a step change in process and reporting after Oncimmune's IPO in May 2016. We wish him well for the future as he seeks to spend more time on his portfolio of directorships and outside interests."

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, John Goold

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Berenberg (Joint Broker)

Toby Flaux, Alix Mecklenburg-Solodkoff

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT(R) -Lung and EarlyCDT(R) -Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT(R) -Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOATFBFTMBJMBBP

(END) Dow Jones Newswires

December 06, 2018 11:34 ET (16:34 GMT)